OBJECTIVES: The objectives of this study were to assess the prevalence of ciprofloxacin-resistant gonorrhoea in two South African cities and to investigate the association between the isolation of ciprofloxacin-resistant Neisseria gonorrhoeae and the HIV serostatus of patients. METHODS: Gonococci were cultured from endourethral swabs taken from consecutive men with urethritis attending clinics in Johannesburg and Cape Town. Minimum inhibitory concentrations (MIC) for ciprofloxacin and ceftriaxone were determined with E-tests. Isolates with a ciprofloxacin MIC of 1 mg/l or greater were defined as resistant and isolates with a ceftriaxone MIC of 0.25 mg/l or less were defined as susceptible. Rapid tests were used to screen and confirm the presence of HIV antibodies. Survey data from 2004 were used as a baseline to assess trends in gonococcal resistance to ciprofloxacin. RESULTS: In 2004, the prevalence of ciprofloxacin resistance was 7% in Cape Town and 11% in Johannesburg. In 2007, 37/139 (27%) Cape Town isolates and 47/149 (32%) Johannesburg isolates were resistant to ciprofloxacin; in comparison with 2004 data, this represents 2.9-fold and 1.9-fold increases, respectively. All isolates were fully susceptible to ceftriaxone. There was a significant association between HIV seropositivity and the presence of ciprofloxacin-resistant gonorrhoea among patients (p = 0.034). CONCLUSIONS: Johannesburg and Cape Town have witnessed significant rises in the prevalence of ciprofloxacin-resistant gonorrhoea among men with urethritis. The resistant phenotype is linked to HIV seropositivity. There is now an urgent need to change national first-line therapy for presumptive gonococcal infections within South Africa.
OBJECTIVES: The objectives of this study were to assess the prevalence of ciprofloxacin-resistant gonorrhoea in two South African cities and to investigate the association between the isolation of ciprofloxacin-resistant Neisseria gonorrhoeae and the HIV serostatus of patients. METHODS: Gonococci were cultured from endourethral swabs taken from consecutive men with urethritis attending clinics in Johannesburg and Cape Town. Minimum inhibitory concentrations (MIC) for ciprofloxacin and ceftriaxone were determined with E-tests. Isolates with a ciprofloxacin MIC of 1 mg/l or greater were defined as resistant and isolates with a ceftriaxone MIC of 0.25 mg/l or less were defined as susceptible. Rapid tests were used to screen and confirm the presence of HIV antibodies. Survey data from 2004 were used as a baseline to assess trends in gonococcal resistance to ciprofloxacin. RESULTS: In 2004, the prevalence of ciprofloxacin resistance was 7% in Cape Town and 11% in Johannesburg. In 2007, 37/139 (27%) Cape Town isolates and 47/149 (32%) Johannesburg isolates were resistant to ciprofloxacin; in comparison with 2004 data, this represents 2.9-fold and 1.9-fold increases, respectively. All isolates were fully susceptible to ceftriaxone. There was a significant association between HIV seropositivity and the presence of ciprofloxacin-resistant gonorrhoea among patients (p = 0.034). CONCLUSIONS: Johannesburg and Cape Town have witnessed significant rises in the prevalence of ciprofloxacin-resistant gonorrhoea among men with urethritis. The resistant phenotype is linked to HIV seropositivity. There is now an urgent need to change national first-line therapy for presumptive gonococcal infections within South Africa.
Authors: Supriya D Mehta; Ian Maclean; Jeckoniah O Ndinya-Achola; Stephen Moses; Irene Martin; Allan Ronald; Lawrence Agunda; Ruth Murugu; Robert C Bailey; Johan Melendez; Jonathan M Zenilman Journal: Antimicrob Agents Chemother Date: 2011-05-23 Impact factor: 5.191
Authors: Philippe R S Lagace-Wiens; Sarah Duncan; Joshua Kimani; Alexander Thiong'o; Juma Shafi; Scott McClelland; Eduard J Sanders; George Zhanel; Nicholas Muraguri; Supriya D Mehta Journal: Sex Transm Dis Date: 2012-05 Impact factor: 2.830
Authors: Said Aboud; Simon N Buhalata; Onduru G Onduru; Mercy G Chiduo; Gideon P Kwesigabo; Stephen E Mshana; Alphaxard M Manjurano; Mansuet M Temu; Coleman Kishamawe; John M Changalucha Journal: Trop Med Infect Dis Date: 2022-06-02
Authors: Ranmini S Kularatne; Tendesayi Kufa; Lindy Gumede; Dumisile V Maseko; David A Lewis Journal: Antimicrob Agents Chemother Date: 2021-08-02 Impact factor: 5.191